Vitamin D Supplementation in Multiple Sclerosis

Description

Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS. In this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.

Study Start Date

March 2012

Estimated Completion Date

June 2018

Interventions

  • Drug: Vitamin D3

Specialties

  • Internal Medicine: Clinical Pharmacology,Neurology
  • Neurology: Demyelinating Disorders
  • Pharmacy: Drug Trials

MeSH Terms

  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting

Study ID

Johns Hopkins University -- NMSS 4407A2/1

Status

Unknown

Trial ID

NCT01490502

Study Type

Interventional

Trial Phase

Phase 3

Enrollment Quota

172

Sponsor

Johns Hopkins University

Inclusion Criteria

    1. Must meet MAGNIMS criteria for relapsing-remitting MS 2. Age 18 to 50 years 3. EDSS score ? 4.0 4. MS disease duration ? 10 years if McDonald RRMS ? 1 year if meets MAGNIMS RRMS criteria but not McDonald RRMS criteria 5. If the patient meets the McDonald RRMS criteria (rather than McDonald CIS that is now classified as MAGNIMS MS):
  • Must have had one clinical attack in past two years AND at least one new silent T2 or gadolinium-enhancing lesion on brain MRI within the past year OR
  • Must have had two clinical attacks in past two years, one of which occurred in the past year 6. Females of child-bearing age must be willing to use at least one form of pregnancy prevention throughout the study. 7. Must have had a 25-hydroxyvitamin D level of ? 15 ng/mL within past 30 days 8. Must be willing to stop taking additional supplemental vitamin D, except as part of a multivitamin, and must be willing to not take cod liver oil.

Exclusion Criteria

    1. Not be pregnant or nursing 2. No ongoing renal or liver disease 3. No known history of nephrolithiasis, hypercalcemia, sarcoidosis or other serious chronic illness including cancer (other than basal cell or squamous cell carcinoma of the skin), cardiac disease, or HIV. 4. No ongoing hyperthyroidism or active infection with Mycobacterium species 5. No known gastrointestinal disease (ulcerative colitis, Crohn's disease, celiac disease/gluten intolerance) or use of medications associated with malabsorption. 6. No history of self-reported alcohol or substance abuse in past six months. 7. No prior history of treatment with rituximab, any chemotherapeutic agent, or total lymphoid irradiation. No treatment in the past six months with natalizumab, fingolimod, or fumarate. If patient has received glatiramer acetate, they have not been exposed to more than three months of treatment. No treatment with other unapproved therapies for MS. 8. No use of interferon beta or glatiramer acetate therapy for one month prior to screening 9. No use of more than 1,000 IU vitamin D3 daily in the three months prior to screening 10. No condition that would limit the likelihood of completing the MRI procedures 11. No use of thiazide diuretics, digoxin, diltiazem, verapamil, cimetidine, heparin, low-molecular weight heparin, phenytoin, phenobarbital, carbamazepine, routine corticosteroids (eg scheduled monthly steroids, daily, etc), rifampin, or cholestyramine. 12. No steroids within a month of screening. 13. Not suicidal at screening visit (ineligible if answers "yes" to question 1 of screening Columbia Suicide Severity Rating Scale (C-SSRS) in PAST 2 MONTHS or answers "yes" to questions 2-5 on C-SSRS for PAST 6 MONTHS or answers "yes" to suicidal attempts or preparatory attempts in PAST 5 YEARS , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225130.pdf). 14. Serum calcium >0.2 mg/dL above upper limit of normal.

Gender

Both

Ages

18 Years to 50 Years

Accepts Healthy Volunteers

No

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Columbia University - New York, New York 44.8 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.